Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07231744
PHASE1
Study of STLX-2012 in Healthy Volunteers
Sponsor: Stelexis BioSciences
View on ClinicalTrials.gov
Summary
The purpose of this research is to establish the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single IV dose of STLX-2012.
Official title: A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of STLX-2012 in Healthy Volunteers
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2026-02
Completion Date
2027-02
Last Updated
2025-11-17
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
STLX-2012
STLX-2012 IV
OTHER
Placebo
Placebo arm
Locations (1)
Nucleus Network Brisbane
Brisbane, Queensland, Australia